Eloralintide Research Peptide

Eloralintide is a long-acting synthetic amylin analogue, developed by Eli Lilly as LY3841136, with a molecular weight of about 4,526 and the CAS number 2883634-40-8. It selectively activates the amylin 1 receptor and has been studied in receptor assays, rats, monkeys and clinical trials now in phase 3. Crown Peptides will supply it in 5mg and 10mg vials.

Yes. LY3841136 was the development code used during early research, and Eloralintide is the international non-proprietary name it was later given. Older conference abstracts and trial registrations use the code, while the published phase 2 results use the name, so searching for both gives the fullest picture of the literature.

It favours one amylin receptor subtype, AMY1R, over the others. In human receptor assays it was about 12-fold more potent at AMY1R than at the calcitonin receptor and about 11-fold more potent than at AMY3R. Earlier long-acting analogues act more evenly across the whole receptor family, so Eloralintide gives researchers a way to study what AMY1R activation does on its own.

They act on completely different hormone systems. GLP-1 compounds mimic a gut hormone released from the intestine, while Eloralintide mimics amylin from the pancreas. Both reduce food intake in research models, but through separate receptors, which is why Lilly is also testing Eloralintide alongside weekly incretin therapy to see how the two pathways combine.

Two design features stretch its half-life. A fatty acid chain on a lysine side chain lets it bind albumin, the most abundant protein in blood, which shields it from rapid clearance, and several unusual amino acids make it harder for enzymes to cut. Pharmacokinetic data in rats, monkeys and people all supported a once-weekly schedule.

It is a rodent test in which animals learn to avoid a flavour they experienced alongside a compound. Strong avoidance suggests the compound made them feel unwell, which can be confused with genuine appetite suppression. Eloralintide caused significantly less conditioned taste avoidance than a non-selective amylin agonist in lean rats, a result the discovery team linked to its receptor selectivity.

In 263 adults with obesity or overweight treated once weekly for 48 weeks, mean body weight fell by 9% at 1mg, 12% at 3mg, 18% at 6mg and 20% at 9mg, against 0.4% on placebo. Waist circumference, blood pressure, lipids and inflammation markers also improved. Nausea and fatigue were the most common side effects, rising with dose and lower with slower dose escalation.

In diet-induced obese rats, the body weight reduction came mainly from fat mass. That is one of the reasons amylin analogues are attracting so much attention in metabolic research, where the quality of weight change matters as much as the amount.

Phase 3 studies are now under way, including trials of Eloralintide on its own in people with obesity or overweight and trials adding it to weekly incretin treatment. A separate phase 2 study is looking at Eloralintide on its own and alongside an incretin-based compound in people with type 2 diabetes, so a large amount of new data is expected over the coming years.

Eloralintide is not a controlled drug under the Misuse of Drugs Act 1971, and it is not a licensed medicine in the UK. It is an investigational compound that has not yet been brought to market, and it is sold in the UK as a research compound for laboratory use only, which is how Crown Peptides supplies it. This is general information, not legal advice.

Eloralintide is coming soon to Crown Peptides in 5mg and 10mg vials, each available singly or in packs of 5 or 10 with a saving on every vial. Orders ship from the UK, and every batch is independently tested, with its Certificate of Analysis published on this page once stock arrives.

The 5mg vial suits receptor assays and pilot work, where only small amounts are used at a time. The 10mg vial gives more material from a single batch for longer animal studies, and choosing one batch for a whole project keeps results comparable from start to finish.

Because it is a large, modified peptide, there are many ways a batch could differ subtly from the intended structure, such as a missing residue or an incomplete fatty acid attachment. Mass spectrometry confirms the molecule has the expected mass of about 4,526, while HPLC shows how much of the material is that single species. Each batch’s Certificate of Analysis documents both.

Keep the unreconstituted powder at -20°C ± 5°C, dry and away from light. Lipidated peptides like Eloralintide can stick to some plastics once in solution, so researchers often use low-binding tubes and validate their own storage conditions for prepared solutions.